
Transmedics Group Inc
NASDAQ:TMDX

Transmedics Group Inc
PP&E Gross
Transmedics Group Inc
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Transmedics Group Inc
NASDAQ:TMDX
|
PP&E Gross
$292.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Becton Dickinson and Co
NYSE:BDX
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Boston Scientific Corp
NYSE:BSX
|
PP&E Gross
$3.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
![]() |
Stryker Corp
NYSE:SYK
|
PP&E Gross
$4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
![]() |
Abbott Laboratories
NYSE:ABT
|
PP&E Gross
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Transmedics Group Inc
Glance View
TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

See Also
What is Transmedics Group Inc's PP&E Gross?
PP&E Gross
292.5m
USD
Based on the financial report for Dec 31, 2024, Transmedics Group Inc's PP&E Gross amounts to 292.5m USD.
What is Transmedics Group Inc's PP&E Gross growth rate?
PP&E Gross CAGR 1Y
62%
Over the last year, the PP&E Gross growth was 62%.